Results 11 to 20 of about 12,025 (204)
Journal of Experimental Pharmacology, 2020 Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, San Filippo Neri Hospital, Rome, Italy; 3Department of ...
Ora J +4 more
doaj +4 more sources
Inhaled long-acting muscarinic antagonists in asthma – A narrative review [PDF]
European Journal of Internal Medicine, 2021 Long-acting muscarinic antagonists (LAMAs) have a recognised role in the management of chronic obstructive pulmonary disease. In asthma, muscarinic antagonists (both short- and long-acting) were historically considered less effective than β2-agonists; only relatively recently have studies been conducted to evaluate the efficacy of LAMAs, as add-on to ...
Papi, Alberto +5 more
openaire +7 more sources
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. [PDF]
Int J Chron Obstruct Pulmon Dis, 2018 A large body of evidence suggests that long-acting β2-adrenoceptor agonist (LABA)/long-acting muscarinic antagonist (LAMA) combinations induce a strong synergistic bronchodilatory effect in human isolated airways. Moreover, a recent post hoc analysis demonstrated clinical synergism between LABAs and LAMAs, which induces a synergistic improvement not ...
Yamada H, Hida N, Hizawa N.
europepmc +6 more sources
Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. [PDF]
Biomed Res Int, 2018 Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient’s severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled corticosteroids (ICS) and long-acting β2-agonsits (LABAs), with the option of supplementary add-on ...
Hamelmann E.
europepmc +4 more sources
Long‐acting muscarinic antagonists and small airways in asthma: Which link? [PDF]
Allergy, 2021 AbstractInvolvement of small airways, those of <2 mm in internal diameter, is present in all stages of asthma and contributes substantially to its pathophysiologic expression. Therefore, small airways are a potential target to achieve optimal asthma control.
Mario Cazzola +2 more
openaire +3 more sources
Understanding the role of long-acting muscarinic antagonists in asthma treatment
Annals of Allergy, Asthma & Immunology, 2022 Long-acting muscarinic antagonists (LAMAs) have been used in the treatment of obstructive pulmonary diseases for years. Long-acting muscarinic antagonists were previously mainly used as bronchodilators in chronic obstructive pulmonary disease, but the use of LAMAs in the treatment of asthma has gained great interest.
Susan, Muiser +3 more
openaire +4 more sources
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium [PDF]
BMC Pulmonary Medicine, 2021 AbstractBackgroundMucociliary clearance (MCC) is an essential defense mechanism in airway epithelia for removing pathogens from the respiratory tract. Impaired ciliary functions and MCC have been demonstrated in asthma and chronic obstructive pulmonary disease (COPD).
Mineo Katsumata +17 more
openaire +3 more sources
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma [PDF]
Allergy, Asthma & Immunology Research, 2017 Despite a range of efficacious therapies for asthma, including inhaled corticosteroids (ICS) and long-acting β₂-agonists (LABA), a significant proportion of patients have poor asthma control and retain a risk of future worsening of their symptoms. Long-acting muscarinic antagonist (LAMA) bronchodilators offer a well-tolerated, efficacious, and cost ...
René Aalbers, Hae-Sim Park
openaire +2 more sources
Novel long‐acting antagonists of muscarinic
British Journal of Pharmacology, 2018 Background and PurposeThe aim of this study was to develop potent and long‐acting antagonists of muscarinic ACh receptors. The 4‐hexyloxy and 4‐butyloxy derivatives of 1‐[2‐(4‐oxidobenzoyloxy)ethyl]‐1,2,3,6‐tetrahydropyridin‐1‐ium were synthesized and tested for biological activity.
Alena Randáková +4 more
openaire +2 more sources
Optimizing asthma management: Role of long-acting muscarinic antagonists
Journal of Allergy and Clinical Immunology, 2022 Patients with asthma who are suboptimally responsive to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) are frequently exposed to oral corticosteroids and high-dose ICS, which can lead to significant side effects. Long-acting muscarinic antagonists (LAMAs) have demonstrated efficacy and safety in a subset of these patients.
Casale, Thomas B +2 more
openaire +3 more sources